Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Michel Dogné

Showing results (1-10 of 199) with videos related to

Pageof 20
Sort By:
Mini Reviews in Medicinal Chemistry|February 7, 2003
Platelet ADP receptors and their antagonistsPatricia Benoit, Jean-Michel Dogné
Expert Review of Cardiovascular Therapy|September 22, 2009
Vascular biology of eicosanoids and atherogenesisDomenico Praticò, Jean-Michel Dogné
Current Pharmaceutical Design|March 15, 2006
Implications of the molecular basis of prostacyclin biosynthesis and signaling in pharmaceutical designsKe-He Ruan, Jean-Michel Dogné
Expert Opinion on Drug Safety|May 22, 2015
Dose tailoring of dabigatran etexilate: obvious or excessive?Jonathan Douxfils, François Mullier, Jean-Michel Dogné
Trends in Pharmacological Sciences|October 26, 2005
Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesisJean-Michel Dogné, Julien Hanson, Domenico Pratico
Therapeutic Advances in Drug Safety|August 29, 2017
A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionalityFrançois Maignen, Manfred Hauben, Jean-Michel Dogné
Molecules (Basel, Switzerland)|April 12, 2017
Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A ReviewValentine Minet, Jean-Michel Dogné, François Mullier
European Journal of Pharmacology|February 7, 2006
Prostanoids as pharmacological targets in COPD and asthmaStéphanie Rolin, Bernard Masereel, Jean-Michel Dogné
Journal of the Endocrine Society|May 15, 2026
Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implicationsEmma Boretti, Jean-Michel Dogné, Jonathan Douxfils
Clinical Pharmacology and Therapeutics|January 20, 2020
An Application of Machine Learning in Pharmacovigilance: Estimating Likely Patient Genotype From Phenotypical Manifestations of Fluoropyrimidine ToxicityLuis Correia Pinheiro, Julie Durand, Jean-Michel Dogné
Pageof 20

Showing results (1-10 of 199) with videos related to

Sort By:
Pageof 20
Mini Reviews in Medicinal Chemistry|February 7, 2003
Platelet ADP receptors and their antagonistsPatricia Benoit, Jean-Michel Dogné
Expert Review of Cardiovascular Therapy|September 22, 2009
Vascular biology of eicosanoids and atherogenesisDomenico Praticò, Jean-Michel Dogné
Current Pharmaceutical Design|March 15, 2006
Implications of the molecular basis of prostacyclin biosynthesis and signaling in pharmaceutical designsKe-He Ruan, Jean-Michel Dogné
Expert Opinion on Drug Safety|May 22, 2015
Dose tailoring of dabigatran etexilate: obvious or excessive?Jonathan Douxfils, François Mullier, Jean-Michel Dogné
Trends in Pharmacological Sciences|October 26, 2005
Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesisJean-Michel Dogné, Julien Hanson, Domenico Pratico
Therapeutic Advances in Drug Safety|August 29, 2017
A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionalityFrançois Maignen, Manfred Hauben, Jean-Michel Dogné
Molecules (Basel, Switzerland)|April 12, 2017
Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A ReviewValentine Minet, Jean-Michel Dogné, François Mullier
European Journal of Pharmacology|February 7, 2006
Prostanoids as pharmacological targets in COPD and asthmaStéphanie Rolin, Bernard Masereel, Jean-Michel Dogné
Journal of the Endocrine Society|May 15, 2026
Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implicationsEmma Boretti, Jean-Michel Dogné, Jonathan Douxfils
Clinical Pharmacology and Therapeutics|January 20, 2020
An Application of Machine Learning in Pharmacovigilance: Estimating Likely Patient Genotype From Phenotypical Manifestations of Fluoropyrimidine ToxicityLuis Correia Pinheiro, Julie Durand, Jean-Michel Dogné
Pageof 20